Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia

Figure 1

Increased levels of TIGIT⁺, TIGTI⁺CD56^bright, and TIGIT⁺CD56^dimCD16⁺ NK cells in DN-CML patients compared with MR patients and HIs. (a) The gating strategy for CD56⁺, CD56^bright, and CD56^dim NK cells and the frequency of TIGIT, CD16, KLRG1, and CD57 on CD56⁺ NK cells are shown. Forward scatter area and height (FSC-H) are used to discriminate single cells. CD45 is used to discriminate the mature white blood cells. Monocytes and B cells are excluded using CD14 and CD19, and T cells are excluded using CD3. CD45^highCD14^-CD19^-CD3^- population expressing CD56⁺, CD56^highCD16⁺, and CD56^dimCD16⁺ is gated as CD56⁺ NK cells, CD56^bright NK cells, and CD56^dim NK cells, respectively, and then, the expression of CD57, TIGIT, and KLRG1 on those NK subsets are analyzed [25]. (b) Summary of the altered distribution of CD56⁺ and CD56^- NK cells within the CD3^- population (left) and CD3^-CD56^bright and CD56^dimCD16⁺ NK cells as well as other cells within the CD3^- population (right) in PB from HIs () and DN-CML () and MR () patients. (c) Frequency of CD56⁺, CD56^bright, and CD56^dimCD16⁺ NK cells in PB from HIs () and DN-CML () and MR () patients. (d) Proportion of TIGIT⁺, TIGTI⁺CD56^bright, and TIGIT⁺CD56^dimCD16⁺ NK cells in PB from HIs () and DN-CML () and MR () patients. All data are shown as . TIGIT: T cell immunoreceptor with Ig and ITIM domain; DN: de novo; CML: chronic myeloid leukemia; HIs: healthy individuals; MR: molecular response. The Mann–Whitney test was used for unpaired sample analysis, and values < 0.05 were considered statistically significant.

(a)

(b)

(c)

(d)